Motilal Oswal's research report on UTI AMC
UTI AMC’s operating revenue grew 29% YoY to INR3.8b (in line). Yields remained flat YoY and QoQ at 42.6bp in 3QFY25. For 9MFY25, revenue grew 26% YoY to INR10.9b. EBITDA was INR1.9b (4% beat) in 3QFY25, +68% YoY, and EBITDA margin improved to 50.8% in 3QFY25 from 39.2% in 3QFY24. Total opex came in at INR1.8b, recording 5% YoY growth. As bp of QAAUM, the costs declined YoY to 21bp in 3QFY25 from 25.8bp in 3QFY24 (vs. 22.2bp in 2QFY25). PAT for the quarter declined 14% YoY/34% QoQ to INR1.7b in 3QFY25 (8% beat). For 9MFY25, PAT grew 15% YoY to INR7.1b.
Outlook
We reiterate our BUY rating with a TP of INR1,300, based on 24x Sep’26E Core EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
